Bayer AG ADR
BAYRY: PINX (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$73.60 | Gfbrmm | Qcqwx |
Bayer's Slowing Innovation and Glyphosate Legal Headwinds Weigh on Competitive Positioning
Business Strategy and Outlook
Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a narrow economic moat. Bayer is evaluating the divestitures of the crop science and consumer healthcare businesses, which appear to hold few synergies with the prescription drug business.